CLINICAL_TRIALS
trial_result
· 2016-06-06
Clinical Trial Update: Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug [Phase 3]
Summary
Phase 3 Japanese study of rimonabant added to oral antidiabetic therapy in obese patients with type 2 diabetes was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Obesity, Diabetes Mellitus Type 2 | Phase 3 | Status: TERMINATED